{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"}],"units":"Participants"}],"description":"Count of participants with HIV progression.","groups":[{"description":"CONDITIONING REGIMEN: Patients receive fludarabine IV over 2 hours on days -4, -3, and -2. Patients undergo TBI on day 0.\n\nTRANSPLANTATION: After completion of TBI, patients undergo allogeneic bone marrow or peripheral blood stem cell transplantation on day 0.\n\nIMMUNOSUPPRESSION: Patients receive cyclosporine IV or PO 2 to 3 times daily on days -3 to 99 with taper beginning on day 100 and continuing until day 177 in the absence of GVHD. Beginning within 6 hours after transplantation, patients also receive mycophenolate mofetil IV or PO 3 times daily on days 0 to 40 followed by a taper in the absence of GVHD.\n\nfludarabine phosphate: Given IV\n\ntotal-body irradiation: Undergo TBI\n\nperipheral blood stem cell transplantation: Undergo allogeneic bone marrow or peripheral blood stem cell transplantation\n\ncyclosporine: Given IV or PO\n\nmycophenolate mofetil: Given IV or PO\n\nlaboratory biomarker analysis: Correlative studies","id":"OG000","title":"Treatment (Allogeneic Hematopoietic Stem Cell Transplantation)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Within 1 year","title":"Progression of HIV","type":"SECONDARY","unitOfMeasure":"Participants"}